English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Herein, folic acid (FA) conjugated Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composites (FA-PL) were developed as nanocarriers for the targeted delivery of insoluble anti-cancer drug paclitaxel (PTX), resulting FA-PLP nanoparticles. Furthermore,  131 I, as a radioactive tracer, was used to label FA-PLP nanoparticles (FA-PLP- 131 I) to evaluate their cell uptake activity, in vivo blood circulation, and biodistribution. The FA-PLP- 131 I nanoparticles had a spherical morphology with great stability, a narrow size distribution (165.6 and 181.2 nm), and −22.1 mV in average zeta potential. Confocal laser scanning microscopy indicated that the targeting molecule FA promotes PLP- 131 I uptake by melanoma B16F10 cells, which was further confirmed by the cell incorporation rate via  131 I activity detection as measured by a gamma counter. FA-PLP- 131 I without PTX (FA-PL- 131 I) shows minor cytotoxicity, good biocompatibility, while FA-PLP- 131 I was demonstrated to have efficient cell viability suppression compared to free PTX and PLP- 131 I. Following intravenous injection, the blood circulation half-life of free PTX ( t   1/2  = 5.4 ± 0.23 h) was prolonged to 18.5 ± 0.5 h by FA-PLP- 131 I. Through FA targeting, the tumor uptake of FA-PLP- 131 I was approximately 4.41- and 12.8-fold higher compared to that of PLP- 131 I and free PTX- 131 I, respectively. Moreover, following 40 days of treatment, FA-PLP- 131 I showed an improved tumor inhibition effect compared to free PTX and PLP- 131 I, with no relapse and no remarkable systemic in vivo toxicity. The results demonstrate that the  131 I-labeled PLGA-lipid nanoparticle can be simultaneously applied for targeted drug delivery and reliable tracking of drugs in vivo.   Electronic supplementary material  The online version of this article (doi:10.1186/s11671-017-2140-7) contains supplementary material, which is available to authorized users.

131I-Traced PLGA-Lipid Nanoparticles as Drug Delivery Carriers for the Targeted Chemotherapeutic Treatment of Melanoma